logo-loader
CVE:ATE

Antibe Therapeutics

Receive alerts
Market:
CVE
Market Cap:
$93.23 m
Price
$0.35
Change
4.55%
52 weeks high
0.40
52 weeks low
0.24

Viewing results 1-14 of 14

Health

Antibe Therapeutics to sell units to raise money to further develop lead osteoarthritis drug

Antibe is working on getting the drug ready for an investigational new drug (IND) application, as well as a meeting with the Food and Drug Administration...

3 weeks, 4 days ago
Health

Antibe Therapeutics hosts successful annual and special general meeting

The firm said shareholders elected six directors at its annual general meeting...

on 07/02/2019
Health

Antibe Therapeutics updates on Phase 2 progress of lead drug ATB-346

Antibe's lead drug, ATB-346, targets acute and chronic pain associated with osteoarthritis and its Phase 2B dose-ranging, efficacy study for the drug remains on track...

on 06/25/2019
Health

Antibe Therapeutics CEO Dan Legault on why the multibillion-dollar NSAID market needs disruption

The Toronto-based biotech company is aiming to build a new generation of NSAIDs to compete against the Bayers and Pfizers of the world...

on 06/07/2019
Health

Antibe Therapeutics targets US$9 billion market with second pipeline drug ATB-352 for severe pain

The Toronto-based company is targeting the postoperative pain sector with ATB-352, a potent and non-addictive drug for the treatment of severe pain...

on 06/03/2019
Health

Antibe Therapeutic's Phase 2B trial safety results for pain drug ATB-346 published in British Journal of Pharmacology

A new research article in the British Journal of Pharmacology highlights the success of Antibe's 2B GI safety trial for its lead pain treatment ATB-346...

on 04/16/2019
Health

Antibe Therapeutics is poised to disrupt the global pain management industry

The biotechnology company is developing a platform of unique drugs designed to prevent serious gastrointestinal damage and bleeding caused by chronic naproxen use...

on 04/12/2019
Health

Antibe grants Kinght commercial rights for drug candidates

The deal covers Antibe's anti-inflammatory and pain drugs in Canada, Israel, Romania, Russia and sub-Saharan Africa....

on 11/16/2015
Health

Antibe Therapeutics seeks to fill market void with “ground-breaking” class of painkiller drugs

Antibe Therapeutics is seeking to fill a vast market void with a “ground-breaking” class of painkiller drugs.  While the journey bringing the drug to market may be long and arduous, the end result appears to be well worth the toil, says president and CEO, Dan Legault. ...

on 10/09/2013